Busadre, Joy D.
HRN: 01-18-25 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/23/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
11/23/2023
11/29/2023
IV
300mg
Q6h
Invasive CA Breast, Left
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes